Tag: major depressive disorder

October 31, 2018

ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial

ACADIA Pharmaceuticals (Nasdaq:ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD)...
June 12, 2018

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced...
May 7, 2018

Landmark Study Shows GeneSight Test Led to Significant Improvement in Mental Health Outcomes for Patients with Major Depressive Disorder

Assurex Health, a wholly-owned subsidiary of Myriad Genetics (NASDAQ:MYGN), today announced that results from a large, well-controlled pharmacogenomics study in...
April 30, 2018

Key Stock Catalysts in the FDA Drug Application Process

Pharmaceutical and biotech companies in the US must follow a standard process to advance a new drug candidate through nonclinical...
April 26, 2018

Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial

Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3.
April 9, 2018

Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

Minerva Neurosciences (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders,...
April 5, 2018

VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today...